馆档网 文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 预防医学 > 联合抗病毒治疗透析HCV的meta(2011)
免费下载此文档侵权投诉

联合抗病毒治疗透析HCV的meta(2011)

JournalofViralHepatitis,2011,18,e263–e269doi:10.1111/j.1365-2893.2010.01405.x

CombinedantiviraltherapyofhepatitisCvirusindialysispatients:meta-analysisofclinicaltrials

DivisionofNephrologyandDialysis,MaggioreHospital,IRCCS

Foundation,Milano,Italy;andDivisionofHepatology,SchoolofMedicine,UniversityofMiami,Miami,FL,USA

2

F.Fabrizi,1,2V.Dixit,2P.Martin2andP.Messa1

1

ReceivedAugust2010;acceptedforpublicationSeptember2010

SUMMARY.Theef cacyandsafetyofcombinedinterferon

(IFN)plusribavirininpatientsonlong-termdialysisandchronichepatitisCremainsunclear,althoughanumberofsmallclinicaltrialshaveaddressedthisissue.Weevaluatedtheef cacyandsafetyofcombinationantiviraltherapy(conventionalorpegylatedinterferonplusribavirin)indialysispatientswithchronichepatitisCbyperformingasystematicreviewoftheliteraturewithameta-analysisofclinicaltrials.Theprimaryoutcomewassustainedvirologi-calresponse(SVR)(asameasureofef cacy);thesecondaryoutcomewasdrop-outrate(asameasureoftolerability).WeusedtherandomeffectsmodelofDerSimonianandLaird,withheterogeneityandsensitivityanalyses.Weidenti ed10clinicalstudies(151uniquepatients),one(10%)ofwhichwasacontrolledclinicaltrial.Most(97.4%)patientswereonlong-termhaemodialysis.ThesummaryestimateforSVR

anddrop-outratewas56%[95%Con denceIntervals(95%CI)28–84]and25%(95%CI,10–40),respectively.Themostfrequentsideeffectsrequiringinterruptionoftreatmentwereanaemia(26%)andheartfailure(9%).Theseresultsoccurredirrespectiveoftypeofinterferon(conventionalorpeg-IFN,peg-IFNalfa-2aoralfa-2b),trialdesign(controlledorcohortstudy),orclinicalcharacteristicsofpatients(na ¨ve,nonrespondersorrelapsers)http://doc.guandang.netbinationantiviraltherapy(interferonplusribavirin)givesencouragingresultsintermsofef cacyandsafetyamongdialysispatientsevenifthelimitednumberofpatientsenrolledinourmeta-analysishampersde nitiveconclusions.

Keywords:dialysis,hepatitisC,interferon,meta-analysis,ribavirin.

INTRODUCTION

ChronichepatitisCvirus(HCV)infectionremainsprevalentinthehaemodialysispopulationdespiteeliminationofHCVfromthebloodsupply,re ecting,inpart,nosocomialspreadwithinhaemodialysisunits[1,2].AlthoughthereisincreasingconcernaboutthedetrimentaleffectofHCVinfectiononsurvivalinpatientswithchronickidneydisease(CKD),therapyofhepatitisCinthispopulationremainschallenging.

ThetreatmentofHCVinpatientsonchronichaemodial-ysisispredicatedonthepremisethatHCVisassociatedwithdecreasedpatientsurvival.Theassociationbetweenanti-HCVpositiveserologicstatusanddiminishedsurvivalinthe

Abbreviations:CKD,chronickidneydisease;EBR,end-of-treatmentbiochemicalresponse;HCV,hepatitisCvirus;IFN,interferon;OTR,on-treatmentresponse;PCR,polymerasechainreaction;RR,relativerisk;SBR,sustainedbiochemicalresponse;SVR,sustainedvirologi-calresponse.

Correspondence:DrFabrizioFabrizi,DivisioneNefrologica,OspedaleMaggiore,Pad.Croff,ViaCommenda15,20122,Milano,Italy.E-mail:fabrizi@policlinico.mi.it

dialysispopulationisalreadyestablished[3]evenifanaccurateassessmentofthenaturalhistoryofHCVinthesepatientsisdif cult[1].Arecentmeta-analysis(sevenobservationalstudiesenrolling11589patientsonmainte-nancedialysis)showedthatthesummaryestimateforadjustedrelativerisk(RR)ofall-causemortalitywithanti-HCVwas1.34witha95%con denceintervalof1.13–1.59[3].Liverdysfunctionhasbeenimplicatedinalowersur-vivalofseropositivepatients;thesummaryestimateforRRofliver-relatedmortalitywithanti-HCVwas3.75(95%CI,1.93;17.99)[3].Theseresultsareconsistentwithevidencefromothersources.Alargesurveyofpatientsondialysisinthreecontinentsreportedanassociationbetweenanti-HCVpositiveserologicstatusandincreasedmortality(RR,1.17;P£0.02)[reviewedinref.4].

Ithadbeensuggestedthatmono-therapywithconven-tionalorpeg-IFNyieldsinferiorresponsesindialysispatientswithchronichepatitisC[4,5].Experiencewithcombinedantiviraltherapy[interferon(IFN)plusribavirin]inpatientswithCKDandhepatitisCislimited.Theprimarygoalofourstudywastosynthesizetheavailableevidenceonthetoler-abilityandef cacyofcombinedantiviraltherapy(conven-tionalorpeg-IFNplusribavirin)inCKDpatientswith

Ó2010BlackwellPublishingLtd

第1页

免费下载Word文档免费下载:联合抗病毒治疗透析HCV的meta(2011)

(下载1-7页,共7页)

我要评论

相关文档

  • HBV HCV相关性肝细胞癌抗病毒治疗专家建议

    HBV HCV相关性肝细胞癌抗病毒治疗专家建议_临床医学_医药卫生_专业资料。临床...Meta分析提示HBV相关性HCC患者应用NAs可降低患 者病死率。Wong等。181收集到9个...

  • 2013 HBV或HCV相关性肝细胞癌抗病毒专家建议

    Journal of Viral Hepatitis 2011;18:e550–e560. 抗病毒治疗对HCC资料的 Meta分析 IFN α对HBV/HCV相关性HCC 治疗可降低病死率 S Breitenstein, et al. ...

  • Meta分析2011

    联合抗病毒治疗透析HCV的m... 暂无评价 7页 2财富值 meta分析 8页 2财富...在Meta分析中,两组总体效应指标的差异。 ? 在Meta分析中,通常要求Effect Size...

  • 血液透析中的HBV和HCV感染

    已知与血液透析治疗相关的趋肝性病毒包括 HBV,HCV,HDV,HGV 和 TT 病毒 等,其中 HBV,HDV 和 HCV 致肝病的作用明确,而 HGV 和 TT 病毒与肝炎的关系尚 未肯定...

  • HBV HCV相关性肝细胞癌抗病毒治疗专家建议 [兼容模式]

    2 ? ? ? ? 相关性HCC 患者检测HBV DNA 阳性,均应给予NAs 抗病毒治疗。在...HCV 相关性HCC 三级预防 ? 10 项临床研究Meta 分析: 645 例HCV 相关性HCC ...

  • HBVHCV相关性肝细胞癌抗病毒治疗专家建议

    专家共识? HBV/HCV相关性肝细胞癌抗病毒治疗 专家建议中华医学会旰病学分会肝癌学组【关键词l 肝细胞; 肝炎病毒,乙型; 治疗on 肝炎病毒,丙型; 癌,l 衰1循证...

  • 特殊人群丙型肝炎抗病毒治疗

    HCV相关肝硬化治疗最新一项meta分析 ? ? ? ? ? 26个中心 568例患者,平均随访达35个月 PEG-IFNα 联合RBV治疗HCV相关肝硬化 总体HCV相关肝硬化患者抗病毒治疗...

  • 2-《HBV+HCV相关性肝细胞癌抗病毒治疗专家建议》解读

    2-《HBV+HCV相关性肝细胞癌抗病毒治疗专家建议》解读_基础医学_医药卫生_专业...Meta 分析证实了 IF N在HCC系统性治疗中的意义。22〕23〕Zhang等〔 和B ...

  • 血液透析中的HBV和HCV感染_黄颂敏

    已知与血液透析治疗相关的趋肝性病毒包括 HBV,HCV,HDV,HGV 和 TT 病毒 等,其中 HBV,HDV 和 HCV 致肝病的作用明确,而 HGV 和 TT 病毒与肝炎的关系尚 未肯定...

站点地图 | 文档上传 | 侵权投诉 | 手机版
新浪认证  诚信网站  绿色网站  可信网站   非经营性网站备案
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  email
返回顶部